Horizon 2020, the EU's framework program for research and development, has granted Lipum a total of EUR 2.2 million to develop SOL-116 for treatment of chronic inflammatory diseases.
"The contribution from Horizon 2020 has been central and giving us the opportunity to develop the drug candidate SOL-116. This has a new mechanism of action and potential to be the first in a new drug class for treatment of chronic inflammatory diseases" says CEO Einar Pontén.
SOL-116 is a therapeutic antibody where the primary focus is on treatment of rheumatism in adults and children. Preparations are underway to start clinical trials in 2022.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 5783495
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.